|
|
|
 |
FDA Approval Activities for this Drug…
Cancidas (caspofungin acetate) Injection, Merck Research NDA 21-227/S-7 1/7/03 1/23/03 1/23/03 Cancidas (caspofungin acetate) Injection, 50 & 70 mg/vial, Merck & Co., NDA 21-227/S-5 11/21/02 12/9/02 11/22/02 Cancidas (caspofungin acetate) Injection, Merck Research NDA 21-227/S-1 & S-3 9/20/02 9/24/02 9/20/02 Cancidas, IV (50 and 70 mg), Merck Research NDA 21-227 1/26/01 10/16/01 Indication: Invasive Aspergillosis Refractory to or Intolerant of Other Therapies Cancidas (caspofungin acetate) Injection, Merck | Cancidas (caspofungin acetate) for Injection, Merck & Co., New or Modified Indication | CANCIDAS (caspofungin acetate) Injection, Merck & Co., Efficacy Supplement | CANCIDAS (caspofungin acetate) Injection, Merck Research, Labeling Revision | Cancidas (caspofungin acetate) I.V. Injection, Merck Research Laboratories, Patient Population Altered | Cancidas (caspofungin acetate) Injection, Merck Research Laboratories, Labeling Revision | Cancidas (caspofungin acetate) I.V. Injection, Merck Research Laboratories, Efficacy Suppl. w/Clinical Data | Cancidas (caspofungin acetate) I.V. Injection, Merck Research Laboratories, Labeling Revision | Cancidas (caspofungin acetate) I.V. Injection, Merck Research Laboratories, Labeling Revision
  
|